ALBRIOZA is now publicly reimbursed by all 10 Canadian provinces

TORONTO, November 27, 2023 - Amylyx Pharmaceuticals Canada announced today that the Company has entered into a Product Listing Agreement with Prince Edward Island (PEI) for the public reimbursement of ALBRIOZA™ (sodium phenylbutyrate and ursodoxicoltaurine) through the PEI Pharmacare Formulary, effective November 27, 2023. ALBRIOZA demonstrated a significant reduction in disease progression and functional decline among individuals diagnosed with ALS in the CENTAUR clinical trial.i This promising outcome has the potential to slow disease progression and provide individuals with ALS with longer periods of functional independence and enhanced quality of life.

“We are thrilled Prince Edward Island has decided to offer public coverage for this treatment,” said Lana Mill, President of the ALS Society of Prince Edward Island. “This fatal condition progresses swiftly, making it critical for eligible Islanders to have access to approved therapies without delay.” 

Prince Edward Island is the tenth and final province to list ALBRIOZA on its public formulary, marking a major celebratory milestone for individuals impacted by ALS in Canada. The federal Non-Insured Health Benefits for First Nations and Inuit and Veterans Affairs Canada plans also provide coverage for ALBRIOZA.

“We deeply value the government of Prince Edward Island’s support for individuals living with ALS by offering public reimbursement for ALBRIOZA,” said Chris Aiello, General Manager and Head of Canada at Amylyx. “This decision ensures those living with ALS who rely on public coverage can now access timely treatment in all provinces in Canada from coast to coast, and we are truly grateful for the support.”  

As ALS progresses, individuals living with the disease experience a gradual loss of mobility, impacting their ability to perform daily activities such as feeding and dressing themselves. Communication and physical contact, such as speaking with and hugging loved ones, become increasingly challenging. Eventually, the disease compromises fundamental vital functions like swallowing and breathing. Due to the aggressive nature of ALS, and as Canadians living with ALS have median life expectancy of two years following diagnosis, there is no time to wait.ii 

About ALS 

ALS is a relentlessly progressive and fatal neurodegenerative disorder caused by motor neuron death in the brain and spinal cord with a median life expectancy of two years from diagnosis.ii Motor neuron loss in ALS leads to deteriorating muscle function, the inability to move and speak, respiratory paralysis and eventually, death.  


ALBRIOZA™ (sodium phenylbutyrate and ursodoxicoltaurine), previously known as AMX0035, is an oral fixed-dose medication approved with conditions to treat amyotrophic lateral sclerosis (ALS) in Canada. It is approved to treat ALS in adults in the U.S. as RELYVRIO®. AMX0035 is being explored for the potential treatment of other neurodegenerative diseases. The formulation of RELYVRIO, ALBRIOZA, and AMX0035 are identical. 

About Amylyx Pharmaceuticals 

Amylyx Pharmaceuticals, Inc. is committed to supporting and creating more moments for the neurodegenerative disease community through the discovery and development of innovative new treatments. Amylyx is headquartered in Cambridge, Massachusetts and has operations in Canada and EMEA. For more information, visit and follow us on LinkedIn and X (previously Twitter).  

For media inquiries, please contact the Amylyx Media Team at +1 (857) 799-7274 or 


i Trial of Sodium Phenylbutyrate–Taurursodiol for Amyotrophic Lateral Sclerosis - NEJM

ii Survival and epidemiology of amyotrophic lateral sclerosis (ALS) cases in the Chicago and Detroit metropolitan cohort: incident cases 2009–2011 and survival through 2018